LYFE Capital
Overview
LYFE Capital is a global healthcare investment platform that focuses on venture opportunities. It invests in the healthcare industry in the US, Singapore, South Korea, Japan and China . With 5 global offices in Asia and the U.S., the firm focuses on investing in critical healthcare supply chain assets, specialized product platforms, and next-generation R&D services, allowing them to grow significant and resilient revenues from global mature markets .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Cytek Biosciences | Nov 2020 | Series D | Co-investor |
| Profound | Jun 2022 | Series A Extension | Co-investor |
| Edge Medical Robotics | Nov 2021 | Series C | Co-investor |
| ImmuneOnco Biopharmaceuticals | Mar 2021 | Series C | Co-investor |
| Shanghai New Pulse Medical Technology | Apr 2018 | Series A | Lead |
For institutional investors. Book with your work email.
Key People
Derek Yuan
Partner
Jing Xu
Partner
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is LYFE Capital based?
LYFE Capital is headquartered in Menlo Park, California, United States.
When was LYFE Capital founded?
LYFE Capital was founded in 2015.
How many portfolio companies does LYFE Capital have?
LYFE Capital has 47 portfolio companies in Caplight's dataset.
What are some companies in LYFE Capital's portfolio?
Portfolio companies visible on Caplight include Cytek Biosciences, Profound, Edge Medical Robotics, ImmuneOnco Biopharmaceuticals, Shanghai New Pulse Medical Technology.
What was LYFE Capital's most recent investment shown here?
LYFE Capital's most recent investment in this portfolio sample was in Profound in 2022.
What sectors does LYFE Capital focus on?
LYFE Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, Enterprise Software, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, Enterprise Software, Frontier & Industrial Tech.
What company stages does LYFE Capital focus on?
LYFE Capital typically invests at the Mid stage.
What is LYFE Capital's AUM?
LYFE Capital's assets under management are estimated between $1.0B and $10.0B.